Asset Details
Do you wish to reserve the book?
Antiviral effect of cannabidiol on K18‐hACE2 transgenic mice infected with SARS‐CoV‐2
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antiviral effect of cannabidiol on K18‐hACE2 transgenic mice infected with SARS‐CoV‐2
Do you wish to request the book?
Antiviral effect of cannabidiol on K18‐hACE2 transgenic mice infected with SARS‐CoV‐2
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antiviral effect of cannabidiol on K18‐hACE2 transgenic mice infected with SARS‐CoV‐2
2024
Overview
The aim of this study was to determine the antiviral activity of cannabidiol (CBD) against SARS‐CoV‐2 infection. CBD is the second most studied cannabinoid obtained from Cannabis plants. We investigated the potential use of CBD, which has so far proven to have a positive effect on different diseases, in the SARS‐CoV‐2 infection. To test this, in vivo studies were carried out using K18‐hACE2 transgenic mice. To reveal the potential therapeutic effect of the CBD at the histopathological and molecular level challenge experiments were performed. The study was designed with two groups (n = 10) and in the treatment group animals were infected with SARS‐CoV‐2 virus strain B.1.1.7 alpha before the administration of CBD. While the disease progressed and resulted in death in the control group that was infected by the virus alone, it was observed that the infection slowed down and the survival rate increased in the mice treated with CBD along with the virus. In this study, K18‐hACE2 transgenic mice infected with the wild SARS‐CoV‐2 virus were used to investigate and prove the antiviral activity of CBD.
Publisher
John Wiley & Sons, Inc
Subject
Angiotensin-Converting Enzyme 2 - genetics
/ Angiotensin-Converting Enzyme 2 - metabolism
/ Animals
/ Antiviral Agents - pharmacology
/ Antiviral Agents - therapeutic use
/ Cannabidiol - therapeutic use
/ Cannabis
/ CBD
/ COVID-19
/ Epilepsy
/ Humans
/ Mice
/ Severe acute respiratory syndrome coronavirus 2
/ Toxicity
/ Viruses
